StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.72 | $1.70 | -1.16% | 0.0M |
| 05-18 | $1.70 | $1.66 | -2.36% | 0.0M |
| 05-19 | $1.68 | $1.55 | -7.74% | 0.0M |
| 05-20 | $1.55 | $1.50 | -3.23% | 0.0M |
| 05-21 | $1.48 | $1.56 | +5.41% | 0.0M |
Next report date, year-over-year trend, and recent quarter history.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Each factor shows AIMD's percentile within the scored universe — observational ranking, not a recommendation.
No sell-side coverage available for AIMD yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $161.00 | $124.16K | $113.04K | $110.87K |
Operating Income | $-2.28M | $-13.99M | $-9.69M | $-6.91M |
Net Income | $-2.46M | $-14.77M | $-10.30M | $-7.37M |
EPS (Diluted) | $-0.41 | $-3.46 | $-2.61 | $-2.02 |
Total Assets | $22.08M | $20.87M | $22.68M | $23.92M |
Total Liabilities | $16.39M | $13.31M | $12.63M | $12.48M |
Cash & Equivalents | $2.84M | $417.35K | $1.13M | $1.22M |
Free Cash Flow OCF − CapEx | $-991.96K | $-4.65M | $-3.80M | $-2.60M |
Shares Outstanding | 6.11M | 5.82M | 4.79M | 4.27M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.